MedTrace Logo

The Metformin Active Surveillance Trial (MAST) Study

NCT01864096 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2024-01-24

No results posted yet for this study

Summary

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

Conditions

Interventions

DRUG

Metformin

One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.

DRUG

Placebo

One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Neil Fleshner, MD, MPH, FRCSC · University Health Network: Department of Surgical Oncology (Urology)

  • Anthony Joshua, MD · University Health Network: Department of Surgical Oncology (Urology)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2024-02-16
Completion
2024-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01864096 on ClinicalTrials.gov